U.S. markets open in 3 hours 4 minutes
  • S&P Futures

    3,827.50
    -0.50 (-0.01%)
     
  • Dow Futures

    31,316.00
    -55.00 (-0.18%)
     
  • Nasdaq Futures

    12,800.75
    -31.00 (-0.24%)
     
  • Russell 2000 Futures

    2,192.10
    -7.90 (-0.36%)
     
  • Crude Oil

    62.97
    -0.56 (-0.88%)
     
  • Gold

    1,759.10
    -16.30 (-0.92%)
     
  • Silver

    26.88
    -0.81 (-2.91%)
     
  • EUR/USD

    1.2105
    -0.0081 (-0.67%)
     
  • 10-Yr Bond

    1.5180
    0.0000 (0.00%)
     
  • Vix

    28.92
    +7.58 (+35.52%)
     
  • GBP/USD

    1.3908
    -0.0104 (-0.75%)
     
  • USD/JPY

    106.3940
    +0.1640 (+0.15%)
     
  • BTC-USD

    46,209.29
    -2,987.54 (-6.07%)
     
  • CMC Crypto 200

    924.65
    -8.49 (-0.91%)
     
  • FTSE 100

    6,594.93
    -57.03 (-0.86%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

STAMFORD, Conn., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 5:00 p.m. PT (8:00 p.m. ET) in San Francisco, CA.

A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA (CR845/difelikefalin), a first-in-class KOR agonist that targets KORs located in the peripheral nervous system, and on immune cells. In a Phase 3 and two Phase 2 trials, KORSUVA (CR845/difelikefalin) Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in pruritus-related quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP), and is currently being investigated in Phase 3 trials in hemodialysis patients with CKD-aP. Oral KORSUVA is in Phase 2 trials for the treatment of pruritus in patients with chronic kidney disease, atopic dermatitis, and primary biliary cholangitis.

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

INVESTOR CONTACT:
Jane Urheim
Stern Investor Relations, Inc.
212-362-1200
jane.urheim@SternIR.com

MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com